Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
- PMID: 16115948
- DOI: 10.1158/1078-0432.CCR-04-2671
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
Abstract
Purpose: We aimed to find key molecules associated with chemoresistance in ovarian cancer using gene expression profiling as a screening tool.
Experimental design: Using two newly established paclitaxel-resistant ovarian cancer cell lines from an original paclitaxel-sensitive cell line and four supersensitive and four refractory surgical ovarian cancer specimens from paclitaxel-based chemotherapy, molecules associated with chemoresistance were screened with gene expression profiling arrays containing 39,000 genes. We further analyzed 44 genes that showed significantly different expressions between paclitaxel-sensitive samples and paclitaxel-resistant samples with permutation tests, which were common in cell lines and patients' tumors.
Results: Eight of these genes showed reproducible results with real-time reverse transcription-PCR, of which indoleamine 2,3-dioxygenase gene expression was the most prominent and consistent. Moreover, by immunohistochemical analysis using a total of 24 serous-type ovarian cancer surgical specimens (stage III, n = 21; stage IV, n = 7), excluding samples used for GeneChip analysis, the Kaplan-Meier survival curve showed a clear relationship between indoleamine 2,3-dioxygenase staining patterns and overall survival (log-rank test, P = 0.0001). All patients classified as negative survived without relapse. The 50% survival of patients classified as sporadic, focal, and diffuse was 41, 17, and 11 months, respectively.
Conclusion: The indoleamine 2,3-dioxygenase screened with the GeneChip was positively associated with paclitaxel resistance and with impaired survival in patients with serous-type ovarian cancer.
Similar articles
-
Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.Oncol Rep. 2007 Jun;17(6):1333-9. Oncol Rep. 2007. PMID: 17487387
-
Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.Oncol Rep. 2006 May;15(5):1265-71. Oncol Rep. 2006. PMID: 16596196
-
Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.Biomed Pharmacother. 2009 Sep;63(8):553-60. doi: 10.1016/j.biopha.2008.04.006. Epub 2008 May 27. Biomed Pharmacother. 2009. PMID: 18571892
-
[Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].Hum Cell. 2001 Dec;14(4):261-6. Hum Cell. 2001. PMID: 11925926 Review. Japanese.
-
Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer.Hum Cell. 2001 Dec;14(4):267-71. Hum Cell. 2001. PMID: 11925927 Review.
Cited by
-
Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers.Cancers (Basel). 2024 Sep 5;16(17):3085. doi: 10.3390/cancers16173085. Cancers (Basel). 2024. PMID: 39272943 Free PMC article. Review.
-
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study.BMC Cancer. 2024 Jul 25;23(Suppl 1):1252. doi: 10.1186/s12885-023-10727-3. BMC Cancer. 2024. PMID: 39054491 Free PMC article. Clinical Trial.
-
TRIF-IFN-I pathway in Helicobacter-induced gastric cancer in an accelerated murine disease model and patient biopsies.iScience. 2024 Mar 8;27(4):109457. doi: 10.1016/j.isci.2024.109457. eCollection 2024 Apr 19. iScience. 2024. PMID: 38558931 Free PMC article.
-
Targeting the immune microenvironment for ovarian cancer therapy.Front Immunol. 2023 Dec 18;14:1328651. doi: 10.3389/fimmu.2023.1328651. eCollection 2023. Front Immunol. 2023. PMID: 38164130 Free PMC article. Review.
-
Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy.Nat Commun. 2023 Nov 9;14(1):7235. doi: 10.1038/s41467-023-43079-4. Nat Commun. 2023. PMID: 37945606 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical